These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38884771)

  • 1. [Not Available].
    Persaud PN; Xhemali X; Neuhaus K; Budev M; Lum J
    Transpl Infect Dis; 2024 Aug; 26(4):e14319. PubMed ID: 38884771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
    Marner M; Kolberg L; Horst J; Böhringer N; Hübner J; Kresna IDM; Liu Y; Mettal U; Wang L; Meyer-Bühn M; Mihajlovic S; Kappler M; Schäberle TF; von Both U
    Microbiol Spectr; 2023 Feb; 11(1):e0443722. PubMed ID: 36692293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
    Stevens RW; Clancy M
    Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Lagacé-Wiens PRS; Schweizer F; Bay D; Lynch JP; Mulvey MR; Zhanel GG
    Microbiol Spectr; 2022 Aug; 10(4):e0172422. PubMed ID: 35758747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in
    Egge SL; Rizvi SA; Simar SR; Alcalde M; Martinez JRW; Hanson BM; Dinh AQ; Baptista RP; Tran TT; Shelburne SA; Munita JM; Arias CA; Hakki M; Miller WR
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0012724. PubMed ID: 38995033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
    Satlin MJ; Simner PJ; Slover CM; Yamano Y; Nagata TD; Portsmouth S
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0019423. PubMed ID: 37347188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
    Matsumoto S; Singley CM; Hoover J; Nakamura R; Echols R; Rittenhouse S; Tsuji M; Yamano Y
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
    Shields RK
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
    Sadek M; Le Guern R; Kipnis E; Gosset P; Poirel L; Dessein R; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2023 Jan; 42(1):61-66. PubMed ID: 36376766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections.
    O'Donnell JN; Bidell MR; Lodise TP
    Pharmacotherapy; 2020 Sep; 40(9):952-969. PubMed ID: 32696452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
    Edgeworth JD; Merante D; Patel S; Young C; Jones P; Vithlani S; Wyncoll D; Roberts P; Jones A; Den Nagata T; Ariyasu M; Livermore DM; Beale R
    Clin Infect Dis; 2019 May; 68(11):1932-1934. PubMed ID: 30418554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Selective Culture Medium for Screening Cefiderocol Resistance in
    Ibrahim A; Bouvier M; Sadek M; Decousser JW; Poirel L; Nordmann P
    J Clin Microbiol; 2023 Jul; 61(7):e0188322. PubMed ID: 37338403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient.
    Arena F; Marchetti L; Henrici De Angelis L; Maglioni E; Contorni M; Cassetta MI; Novelli A; Rossolini GM
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642936
    [No Abstract]   [Full Text] [Related]  

  • 18. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
    Hakki M; Lewis JS
    Infection; 2018 Jun; 46(3):431-434. PubMed ID: 29460229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa.
    Mueller SW; Molina KC; Blass B; Gibson C; Kohler AD; Krsak M; Wiktor AJ
    J Burn Care Res; 2024 May; 45(3):808-810. PubMed ID: 38422368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.
    Heil EL; Lowery AV; Thom KA; Nicolau DP
    Pharmacotherapy; 2015 Jan; 35(1):54-8. PubMed ID: 25556715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.